{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:12:06Z","timestamp":1790745126146,"version":"4.1.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.01315","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T04:54:39Z","timestamp":1576126479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":83,"title":["Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases"],"prefix":"10.3389","volume":"10","author":[{"given":"Bindu D.","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon H.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1126\/science.117.3049.633","article-title":"Protection against x-rays and therapy of radiation sickness with beta-mercaptoethylamine","volume":"117","author":"Bacq","year":"1953","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3181\/00379727-84-20758","article-title":"Studies with cysteinamine and cysteine in x-irradiated animals","volume":"84","author":"Straube","year":"1953","journal-title":"Proc Soc Exp Biol Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1126\/science.118.3078.776","article-title":"Failure of mercaptoethylamine to protect against the mutagenic effects of radiation. I Experiments with Drosophila","volume":"118","author":"Kaplan","year":"1953","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.118.3078.777","article-title":"Failure of mercaptoethylamine to protect against the mutagenic effects of radiation. II Experiments with mice","volume":"118","author":"Kaplan","year":"1953","journal-title":"Science."},{"key":"B5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0021-9258(18)65696-0","article-title":"Biosynthesis of coenzyme A from phospho-pantetheine and of pantetheine from pantothenate","volume":"207","author":"Hoagland","year":"1954","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-0-387-33504-9_3","article-title":"Cysteamine dioxygenase: evidence for the physiological conversion of cysteamine to hypotaurine in rat and mouse tissues","volume":"583","author":"Coloso","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1152\/physrev.1992.72.1.101","article-title":"Physiological actions of taurine","volume":"72","author":"Huxtable","year":"1992","journal-title":"Physiol Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0014-5793(00)02110-4","article-title":"Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice","volume":"483","author":"Pitari","year":"2000","journal-title":"FEBS Lett"},{"key":"B9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0076-6879(87)43027-9","article-title":"Cysteamine and cystamine","volume":"143","author":"Duffel","year":"1987","journal-title":"Methods Enzymol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainres.2007.05.007","article-title":"Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: central role of free cysteine and cysteamine","volume":"1158","author":"Wood","year":"2007","journal-title":"Brain Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1139\/y92-004","article-title":"Cysteamine in combination with N-acetylcysteine prevents acetaminophen-induced hepatotoxicity","volume":"70","author":"Peterson","year":"1992","journal-title":"Can J Physiol Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2220\/biomedres.35.389","article-title":"Acrolein, a highly toxic aldehyde generated under oxidative stress in vivo, aggravates the mouse liver damage after acetaminophen overdose","volume":"35","author":"Arai","year":"2014","journal-title":"Biomed Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ab.2005.03.051","article-title":"A continuous spectrophotometric assay for human cystathionine beta-synthase","volume":"342","author":"Shen","year":"2005","journal-title":"Anal Biochem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1016\/j.jchromb.2009.05.041","article-title":"Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism","volume":"877","author":"Pinto","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1259\/0007-1285-33-392-512","article-title":"A trial of cystamine in radiation sickness","volume":"33","author":"Healy","year":"1960","journal-title":"Br J Radiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ng0498-319","article-title":"A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis","volume":"18","author":"Town","year":"1998","journal-title":"Nat Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMra020552","article-title":"Cystinosis","volume":"347","author":"Gahl","year":"2002","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrneph.2016.182","article-title":"The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives","volume":"13","author":"Cherqui","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.exppara.2010.02.009","article-title":"Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium","volume":"125","author":"Min-Oo","year":"2010","journal-title":"Exp Parasitol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1128\/AAC.01719-09","article-title":"Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin","volume":"54","author":"Min-Oo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/aid.1995.11.451","article-title":"Cystamine inhibits HIV type 1 replication in cells of monocyte\/macrophage and T cell lineages","volume":"11","author":"Ho","year":"1995","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/infdis\/174.1.214","article-title":"In vitro inhibition of the replication of human immunodeficiency virus type 1 by beta-mercaptoethylamine (cysteamine)","volume":"174","author":"Bergamini","year":"1996","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1196\/annals.1391.033","article-title":"New molecular mechanisms of duodenal ulceration","volume":"1113","author":"Szabo","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1073\/pnas.73.9.3288","article-title":"Inhibition of erythrocyte sickling by cystamine, a thiol reagent","volume":"73","author":"Hassan","year":"1976","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jnr.10702","article-title":"Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells","volume":"74","author":"Ientile","year":"2003","journal-title":"J Neurosci Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1292\/jvms.16-0325","article-title":"Acrolein scavengers, cysteamine and N-benzylhydroxylamine, reduces the mouse liver damage after acetaminophen overdose","volume":"78","author":"Koyama","year":"2017","journal-title":"J Vet Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jcmm.12107","article-title":"Effects of cystamine on antioxidant activities and regulatory T cells in lupus-prone mice","volume":"17","author":"Hsu","year":"2013","journal-title":"J Cell Mol Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cryobiol.2014.05.004","article-title":"Different concentrations of cysteamine and ergothioneine improve microscopic and oxidative parameters in ram semen frozen with a soybean lecithin extender","volume":"69","author":"Najafi","year":"2014","journal-title":"Cryobiology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/cns.12343","article-title":"Cystamine improves functional recovery via axon remodeling and neuroprotection after stroke in mice","volume":"21","author":"Li","year":"2015","journal-title":"CNS Neurosci Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pnpbp.2009.11.005","article-title":"Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor","volume":"34","author":"Gibrat","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainres.2010.03.079","article-title":"Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice","volume":"1335","author":"Sun","year":"2010","journal-title":"Brain Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.expneurol.2010.04.008","article-title":"Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription","volume":"224","author":"Calkins","year":"2010","journal-title":"Exp Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1534\/genetics.115.184648","article-title":"A pharmacogenetic discovery: cystamine protects against haloperidol-induced toxicity and ischemic brain injury","volume":"203","author":"Zhang","year":"2016","journal-title":"Genetics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s11064-017-2258-0","article-title":"Transglutaminases derived from astrocytes accelerate amyloid beta aggregation","volume":"42","author":"Kawabe","year":"2017","journal-title":"Neurochem Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1471-4159.2004.02726.x","article-title":"Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation","volume":"91","author":"Fox","year":"2004","journal-title":"J Neurochem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1073\/pnas.0438021100","article-title":"Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies","volume":"100","author":"Junn","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J Neurosci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/toxsci\/kft199","article-title":"Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells\u2013protective effect of cystamine and creatine","volume":"136","author":"Ribeiro","year":"2013","journal-title":"Toxicol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1460-9568.2006.04686.x","article-title":"Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells","volume":"23","author":"Mao","year":"2006","journal-title":"Eur J Neurosci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/jnc.12441","article-title":"Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1","volume":"128","author":"Oono","year":"2014","journal-title":"J Neurochem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"34ra40","DOI":"10.1126\/scitranslmed.3000723","article-title":"Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy","volume":"2","author":"Davies","year":"2010","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000327773","article-title":"Effect of cystamine on blood pressure and vascular characteristics in spontaneously hypertensive rats","volume":"48","author":"Engholm","year":"2011","journal-title":"J Vasc Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1681\/ASN.2012090962","article-title":"Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD","volume":"25","author":"Okamura","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1167\/iovs.11-8636","article-title":"Cysteamine prevents the development of lens opacity in a rat model of selenite-induced cataract","volume":"53","author":"Lee","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1039\/C6TX00409A","article-title":"Cystamine attenuated behavioral deficiency via increasing the expression of BDNF and activating PI3K\/Akt signaling in 2,5-hexanedione intoxicated rats","volume":"6","author":"Wang","year":"2017","journal-title":"Toxicol Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pnpbp.2010.11.023","article-title":"Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases","volume":"35","author":"Gibrat","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1111\/j.1471-4159.2010.06874.x","article-title":"Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases","volume":"114","author":"Bousquet","year":"2010","journal-title":"J Neurochem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1097-2765(00)80059-3","article-title":"Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine","volume":"1","author":"Kahlem","year":"1998","journal-title":"Mol Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1073\/pnas.96.13.7388","article-title":"Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei","volume":"96","author":"Karpuj","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/pro.2162","article-title":"Regulation of the activities of the mammalian transglutaminase family of enzymes","volume":"21","author":"Klock","year":"2012","journal-title":"Protein Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e99520","DOI":"10.1371\/journal.pone.0099520","article-title":"Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6\/2 and zQ175 mouse models of Huntington's disease","volume":"9","author":"Menalled","year":"2014","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nbd.2010.04.007","article-title":"Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease","volume":"40","author":"Bortvedt","year":"2010","journal-title":"Neurobiol Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03255.x","article-title":"Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease","volume":"94","author":"Pinto","year":"2005","journal-title":"J Neurochem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature13136","article-title":"Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington's disease","volume":"509","author":"Paul","year":"2014","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1073\/pnas.1608264113","article-title":"Transcriptional control of amino acid homeostasis is disrupted in Huntington's disease","volume":"113","author":"Sbodio","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B58","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.tips.2018.02.007","article-title":"Cysteine metabolism in neuronal redox homeostasis","volume":"39","author":"Paul","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrm3391","article-title":"H(2)S signalling through protein sulfhydration and beyond","volume":"13","author":"Paul","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/ars.2014.5917","article-title":"Modes of physiologic H2S signaling in the brain and peripheral tissues","volume":"22","author":"Paul","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"B61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bcp.2017.11.019","article-title":"Gasotransmitter hydrogen sulfide signaling in neuronal health and disease","volume":"149","author":"Paul","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease","volume":"103","author":"Ryu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease","volume":"21","author":"Dubinsky","year":"2006","journal-title":"Mov Disord"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pages","year":"2006","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JHD-180312","article-title":"Cysteamine protects neurons from mutant huntingtin toxicity","volume":"8","author":"Arbez","year":"2019","journal-title":"J Huntingtons Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur J Neurol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1212\/WNL.0b013e318266fc77","article-title":"Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia","volume":"79","author":"Balasubramanian","year":"2012","journal-title":"Neurology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.24125","article-title":"Mild to moderate Alzheimer dementia with insufficient neuropathological changes","volume":"75","author":"Serrano-Pozo","year":"2014","journal-title":"Ann Neurol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"104530","DOI":"10.1016\/j.nbd.2019.104530","article-title":"Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial","volume":"130","author":"Cicchetti","year":"2019","journal-title":"Neurobiol Dis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","article-title":"Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology","volume":"7","author":"Radde","year":"2006","journal-title":"EMBO Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.neuropharm.2011.10.007","article-title":"Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment","volume":"62","author":"Minarini","year":"2012","journal-title":"Neuropharmacology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbadis.2007.12.006","article-title":"Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease","volume":"1782","author":"Stack","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"B75","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.neurobiolaging.2005.04.004","article-title":"Neuroprotective effects of cystamine in aged parkinsonian mice","volume":"27","author":"Tremblay","year":"2006","journal-title":"Neurobiol Aging"},{"key":"B76","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: from genes to mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.32607\/20758251-2013-5-2-81-89","article-title":"Factors affecting aggregate formation in cell models of huntington's disease and amyotrophic lateral sclerosis","volume":"5","author":"Lazarev","year":"2013","journal-title":"Acta Nat."},{"key":"B80","first-page":"254","article-title":"Neurobehavioral consequences of a genetic metabolic disorder: visual processing deficits in infantile nephropathic cystinosis","volume":"13","author":"Ballantyne","year":"2000","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4103\/1319-2442.144256","article-title":"Neurocognitive functions and behavioral profiles in children with nephropathic cystinosis","volume":"25","author":"Aly","year":"2014","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B82","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jpeds.2016.12.054","article-title":"Neurocognitive complications of cystinosis","author":"Trauner","year":"2017","journal-title":"J Pediatr"},{"key":"B83","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jpeds.2013.01.027","article-title":"Effect of age at treatment on cognitive performance in patients with cystinosis","volume":"163","author":"Viltz","year":"2013","journal-title":"J Pediatr"},{"key":"B84","doi-asserted-by":"publisher","first-page":"103578","DOI":"10.1016\/j.bandc.2019.103578","article-title":"Visual and verbal learning and memory in cystinosis","volume":"135","author":"Frankel","year":"2019","journal-title":"Brain Cogn"},{"key":"B85","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B86","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.schres.2014.06.030","article-title":"Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia","volume":"158","author":"Buckley","year":"2014","journal-title":"Schizophr Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.mehy.2006.10.045","article-title":"Therapeutic possibilities of cysteamine in the treatment of schizophrenia","volume":"69","author":"Pae","year":"2007","journal-title":"Med Hypotheses"},{"key":"B88","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.brainresbull.2019.08.005","article-title":"Neurochemical evidence that cysteamine modulates amphetamine-induced dopaminergic neuronal activity in striatum by decreasing dopamine release: an in vivo microdialysis study in freely moving rats","volume":"153","author":"Rakovska","year":"2019","journal-title":"Brain Res Bull"},{"key":"B89","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1471-4159.2008.05665.x","article-title":"Cystamine prevents haloperidol-induced decrease of BDNF\/TrkB signaling in mouse frontal cortex","volume":"107","author":"Pillai","year":"2008","journal-title":"J Neurochem"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.pnpbp.2008.06.003","article-title":"Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice","volume":"32","author":"Shieh","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B91","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0091-3057(97)00020-8","article-title":"Cysteamine blocks amphetamine-induced deficits in sensorimotor gating","volume":"58","author":"Feifel","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1017\/S1461145711001180","article-title":"Cysteamine treatment ameliorates alterations in GAD67 expression and spatial memory in heterozygous reeler mice","volume":"15","author":"Kutiyanawalla","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2019091","DOI":"10.1155\/2018\/2019091","article-title":"Transglutaminase 2 induces deficits in social behavior in mice","volume":"2018","author":"Crider","year":"2018","journal-title":"Neural Plast"},{"key":"B94","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.neuron.2007.10.001","article-title":"The story of Rett syndrome: from clinic to neurobiology","volume":"56","author":"Chahrour","year":"2007","journal-title":"Neuron"},{"key":"B95","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.nbd.2011.11.002","article-title":"Modification of Mecp2 dosage alters axonal transport through the Huntingtin\/Hap1 pathway","volume":"45","author":"Roux","year":"2012","journal-title":"Neurobiol Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e26153","DOI":"10.1371\/journal.pone.0026153","article-title":"Cysteamine attenuates the decreases in TrkB protein levels and the anxiety\/depression-like behaviors in mice induced by corticosterone treatment","volume":"6","author":"Kutiyanawalla","year":"2011","journal-title":"PLoS ONE."},{"key":"B97","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.26101","article-title":"A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease","volume":"30","author":"Prundean","year":"2015","journal-title":"Mov Disord"},{"key":"B98","doi-asserted-by":"publisher","first-page":"14D","DOI":"10.1016\/j.amjcard.2008.02.003","article-title":"Why have antioxidants failed in clinical trials?","volume":"101","author":"Steinhubl","year":"2008","journal-title":"Am J Cardiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"427318","DOI":"10.1155\/2014\/427318","article-title":"Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?","volume":"2014","author":"Persson","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"B100","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","article-title":"The role of oxidative stress in neurodegenerative diseases","volume":"24","author":"Kim","year":"2015","journal-title":"Exp Neurobiol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s11095-016-2068-0","article-title":"Why have clinical trials of antioxidants to prevent neurodegeneration failed? - A cellular investigation of novel phenothiazine-type antioxidants reveals competing objectives for pharmaceutical neuroprotection","volume":"34","author":"Ohlow","year":"2017","journal-title":"Pharm Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1093\/hmg\/ddq253","article-title":"Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease","volume":"19","author":"Underwood","year":"2010","journal-title":"Hum Mol Genet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.4161\/15548627.2014.973737","article-title":"Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation","volume":"10","author":"De Stefano","year":"2014","journal-title":"Autophagy"},{"key":"B104","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17425247.2019.1575807","article-title":"Novel cystamine-core dendrimer-formulation rescues DeltaF508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy","volume":"16","author":"Faraj","year":"2019","journal-title":"Expert Opin Drug Deliv"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01315\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T21:06:13Z","timestamp":1613077573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01315\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":104,"alternative-id":["10.3389\/fneur.2019.01315"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.01315","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"article-number":"1315"}}